We are live on ! Find out more
TRVI icon

Trevi Therapeutics
TRVI

55 hedge funds and large institutions have $106M invested in Trevi Therapeutics in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 13 increasing their positions, 17 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 4

4% more funds holding

Funds holding: 53 → 55 (+2)

5.03% less ownership

Funds ownership: 81.28% → 76.25% (-5%)

9% less capital invested

Capital invested by funds: $117M → $106M (-$10.6M)

24% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 17

Holders
55
Holders Change
+2
Holders Change %
+3.77%
% of All Funds
0.87%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
13
Reduced
17
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$101K
2
SCM
Silverarc Capital Management
Massachusetts
+$93.7K
3
State Street
State Street
Massachusetts
+$63.3K
4
Deutsche Bank
Deutsche Bank
Germany
+$56.6K
5
Jane Street
Jane Street
New York
+$55.6K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$196K
2
MCM
MAI Capital Management
Ohio
-$188K
3
IAM
Innovis Asset Management
Illinois
-$103K
4
Citadel Advisors
Citadel Advisors
Florida
-$75.4K
5
FFM
Fairmount Funds Management
Pennsylvania
-$61.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
AI
26
Atom Investors
Texas
$84K +$323 +143 +0.4%
New York State Common Retirement Fund
27
New York State Common Retirement Fund
New York
$80.2K +$1.1K +485 +1%
Morgan Stanley
28
Morgan Stanley
New York
$75.7K -$6.95K -3,077 -8%
Bank of America
29
Bank of America
North Carolina
$62.5K -$20.1K -8,897 -24%
UBV
30
United Bank (Virginia)
Virginia
$62K – – –
Citadel Advisors
31
Citadel Advisors
Florida
$59K -$75.4K -33,372 -55%
JP Morgan Chase
32
JP Morgan Chase
New York
$58.8K -$14K -6,189 -19%
Goldman Sachs
33
Goldman Sachs
New York
$57K -$20.1K -8,901 -25%
Deutsche Bank
34
Deutsche Bank
Germany
$54.7K +$56.6K +25,070 New
Jane Street
35
Jane Street
New York
$53.6K +$55.6K +24,600 New
UBS Group
36
UBS Group
Switzerland
$49.2K -$3.34K -1,480 -6%
American Century Companies
37
American Century Companies
Missouri
$46.7K +$48.4K +21,427 New
AIG
38
American International Group
New York
$45.3K +$1.67K +738 +4%
SG Americas Securities
39
SG Americas Securities
New York
$43K +$44.3K +19,597 New
Dimensional Fund Advisors
40
Dimensional Fund Advisors
Texas
$40.1K +$41.5K +18,382 New
VOYA Investment Management
41
VOYA Investment Management
Georgia
$38.1K – – –
Invesco
42
Invesco
Georgia
$35K – – –
Barclays
43
Barclays
United Kingdom
$29K -$1.73K -767 -5%
Wells Fargo
44
Wells Fargo
California
$22.4K -$12.6K -5,562 -35%
BNP Paribas Financial Markets
45
BNP Paribas Financial Markets
France
$21.1K -$2.67K -1,183 -11%
California State Teachers Retirement System (CalSTRS)
46
California State Teachers Retirement System (CalSTRS)
California
$20K -$10.5K -4,663 -34%
SO
47
STRS Ohio
Ohio
$18K – – –
Royal Bank of Canada
48
Royal Bank of Canada
Ontario, Canada
$15K +$5.98K +2,645 +61%
TRCT
49
Tower Research Capital (TRC)
New York
$14.1K +$11.2K +4,951 +330%
AB
50
Amalgamated Bank
New York
$9K – – –
1
2
3

TRVI Hedge Fund Activity: Q3 2023 in Review

55 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Trevi Therapeutics (TRVI) for Q3 2023, worth a combined $106M — down 9% from $117M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new TRVI positions and 4 closed out — a net gain of 2 holders — while 13 added to existing stakes and 17 trimmed.

The largest buyer was Vanguard Group, adding an estimated $101K. The largest seller was BlackRock, cutting an estimated $196K.

  • 55 institutional investors held Trevi Therapeutics (TRVI) as of Q3 2023, up from 53 in Q2 2023.
  • Funds reported $106M of Trevi Therapeutics stock for Q3 2023, down 9% quarter-over-quarter.
  • 6 funds opened new Trevi Therapeutics positions in Q3 2023 and 4 closed out, a net change of +2 holders.
  • The largest Trevi Therapeutics buyer in Q3 2023 was Vanguard Group, an estimated $101K added.
  • The largest Trevi Therapeutics seller in Q3 2023 was BlackRock, an estimated $196K sold.

Based on aggregated 13F filings for Q3 2023.